Investment Rating - The report maintains an investment rating of "Outperform the Market" for the biopharmaceutical industry [1]. Core Viewpoints - The innovation capabilities of Chinese pharmaceutical companies are steadily improving, attracting significant attention from multinational corporations (MNCs) [4]. - The domestic innovative drug market is experiencing a transformation from quantity to quality, with a notable increase in the number of license-out transactions [4][9]. - The Chinese innovative drug sector is supported by favorable policies, creating a conducive environment for development [6]. - Recent strong performance in the Hong Kong biotech sector is attributed to previously low valuations and the rising interest in AI-related stocks [7]. Summary by Sections Industry Overview - Chinese pharmaceutical companies are gaining recognition for their innovative capabilities, with a historical high of 88 license-out transactions expected in 2024, marking a 10% increase [4]. - The global rights for the drug furmonertinib were licensed to Takeda for up to $1.13 billion, setting a record for Chinese small molecule drug licensing [4]. Market Performance - Innovative drugs from China are achieving rapid commercialization abroad, with BeiGene's core drug, the BTK inhibitor Brukinsa, surpassing $1 billion in global sales for the first time, reaching $1.3 billion in 2023 [5]. - Legend Biotech's CAR-T product Carvykti is projected to achieve $963 million in revenue in 2024, a 93% increase [5]. Policy Support - The Chinese government is actively supporting the development of innovative drugs through various policies, including the implementation of a comprehensive plan to support innovative drug development [6]. - The introduction of a new category of drugs (Class C) in the basic medical insurance directory is aimed at covering highly innovative drugs that provide significant clinical value [6]. Investment Strategy - The report suggests focusing on companies with strong innovation capabilities and potential for international expansion, such as BeiGene, Legend Biotech, and others [24][25]. - It emphasizes the importance of the "innovation" and "outbound" themes in investment strategies [24]. Key Companies to Watch - Companies like Yuan Dong Biology, Jianyou Co., and others are highlighted for their innovative pipelines and market potential [27][30]. - BeiGene is noted for its leadership in the blood cancer field and its strategic partnerships for global commercialization [30].

Investment Rating - The report gives a "Recommended" rating for the company, Haohai Biological Technology [1]. Core Viewpoints - Haohai Biological Technology is a leading innovator in biomedicine materials, focusing on medical aesthetics and artificial crystalline lenses as its main growth drivers [10][15]. - The company has shown significant revenue growth in its core products, particularly hyaluronic acid and artificial crystalline lenses, with a projected increase in net profit for the coming years [5][17]. - The medical aesthetics sector is identified as a second growth curve for the company, with a strong market presence and potential for further market share expansion [25][29]. Summary by Sections Company Overview - Haohai Biological Technology, established in 2007, specializes in the research, production, and sales of medical biopolymer materials, covering fields such as ophthalmology, medical aesthetics, wound care, orthopedics, and surgery [10][15]. - The company is a major supplier of artificial crystalline lenses in China, with a stable and concentrated shareholding structure [12][15]. Financial Performance - The company reported a revenue of 2,130 million yuan in 2022, with a projected increase to 3,468 million yuan by 2026, reflecting a compound annual growth rate [5]. - In 2023, the company achieved a net profit of 4.2 billion yuan, a significant increase of 130.6% year-on-year, driven by stable production and sales recovery [17][18]. Product Analysis - The main products include hyaluronic acid and artificial crystalline lenses, with 2023 revenues of 6.0 billion yuan (+95.5%) and 3.8 billion yuan (+37%), respectively [7][15]. - The company has a diverse product matrix in hyaluronic acid, with three main products: Haiwei, Jiaolan, and Haimei, catering to different market segments [29][33]. Market Potential - The artificial crystalline lens market is expected to grow due to an aging population and increasing demand for cataract surgeries, with the market size reaching 25.5 billion yuan in 2022 [38][41]. - The report highlights the potential for domestic brands to capture market share from imported high-end products, particularly in the context of national procurement policies [43][45]. Competitive Landscape - The report compares Haohai Biological Technology with peers such as Aibo Medical and Huaxi Biological, suggesting an average valuation of 28 times for comparable companies [7][54]. - The company is positioned to benefit from ongoing trends in the medical aesthetics market, with a focus on innovation and product development [28][29].

海外宏观 2025 年 2 月 23 日 海外宏观周报 美国经济"亮红灯" 证券分析师 | 钟正生 | 投资咨询资格编号 | | --- | --- | | | S1060520090001 | | | ZHONGZHENGSHENG934@pingan.com.cn | | 张璐 | 投资咨询资格编号 | | | S1060522100001 | | | ZHANGLU150@pingan.com.cn | | 范城恺 | 投资咨询资格编号 | | | S1060523010001 | | | FANCHENGKAI146@pingan.com.cn | 平安观点： 宏 观 报 告 宏 观 周 报 证 券 研 究 报 告 请通过合法途径获取本公司研究报告，如经由未经许可的渠道获得研究报告，请慎重使用并注意阅读研究报告尾页的声明内容。 海外经济政策。1）美国：美联储 1 月会议纪要保持对降息的谨慎态度，新 增有关放缓或暂停缩表的讨论。多位美联储官员发言表示警惕通胀风险，谨 慎对待降息。特朗普扬言将对汽车、药品、芯片和木材加征 25%关税。 美国 2 月密歇根消费信心终值下修，5 年通胀预期上修。美国 2 月 ...

其 他 报 告 2025年02月24日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3379 | 0.85 | 0.97 | | 深证成份指数 | 10991 | 1.82 | 2.25 | | 沪深300指数 | 3978 | 1.26 | 1.00 | | 创业板指数 | 2282 | 2.51 | 2.99 | | 上证国债指数 | 224 | -0.08 | -0.28 | | 上证基金指数 | 7146 | 1.91 | 2.10 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 23478 | 3.99 | 3.79 | | 中国香港国企指数 | 8667 | 4.14 | 4.02 | | 中国台湾加权指数 | 23730 | 1.03 | 2.49 | | 道琼斯指数 | 43428 | -1.69 | ...

有色金属与新材料 2025 年 2 月 23 日 有色金属与新材料周报 供给约束渐显，关注工业金属"硬商品"定价逻辑 强于大市（维持） 行情走势图 -20% -10% 0% 10% 20% 30% 24/01 24/04 24/07 24/10 25/01 沪深300 有色金属 证券分析师 陈潇榕 投资咨询资格编号 S1060523110001 chenxiaorong186@pingan.com.cn 马书蕾 投资咨询资格编号 S1060524070002 mashulei362@pingan.com.cn 核心观点： 行 业 报 告 行 业 报 告 行 业 深 度 报 行 业 深 度 报 行 业 周 报 证 券 研 究 报 告 请通过合法途径获取本公司研究报告，如经由未经许可的渠道获得研究报告，请慎重使用并注意阅读研究报告尾页的声明内容。 告 告 贵金属-黄金：短期波动加剧，长期仍看上行。 截至 2.21，COMEX 金主力合约环比上涨 1.93%至 2949.6 美元/盎司；SPDR 黄金 ETF增 加 4.8%至 904.38 吨。特朗普签署关税对等备忘录，但细节仍待落 地，关税引发的避险情绪仍存。美 ...

食品饮料周报 酒厂密集停货，加大供给侧管控 证券研究报告 食品饮料行业 强于大市（维持） 平安证券研究所 食品饮料团队 分析师：张晋溢 S1060521030001（证券投资咨询） 邮箱：ZHANGJINYI112@pingan.com.cn 分析师：王萌 S1060522030001（证券投资咨询） 邮箱：WANGMENG917@pingan.com.cn 分析师：王星云 S1060523100001（证券投资咨询） 邮箱：WANGXINGYUN937@pingan.com.cn 2025年2月24日 请务必阅读正文后免责条款 食品饮料周报-观点 白酒行业 食品行业 资料来源：iFind，平安证券研究所 本周白酒指数（中信）累计涨跌幅+0.51%。涨跌幅前三的个股为：山西汾酒（+1.65%）、今世缘（+1.55%）、古井贡酒 （+1.15%）；涨跌幅后三的个股为伊力特（-1.70%）、顺鑫农业（-2.05%）、迎驾贡酒（-3.69%）。 观点：酒厂密集停货，加大供给侧管控。受人工智能等因素催化，上周市场成交较活跃，而白酒板块关注度相对较低，略跑输大盘。 与此同时，春节以来酒厂密集停货，加大供给侧管控，有望加 ...

Investment Rating - The industry investment rating is "stronger than the market," indicating that the industry index is expected to outperform the market by more than 5% within the next six months [26]. Core Insights - Australian pension funds plan to expand investments in the U.S. to encourage the U.S. to abandon tariff plans against Australia. The Australian pension industry currently has an AUM of $2.6 trillion, with about one-third of private equity investments located in the U.S. [9][10] - The French Audit Court reports that the pension system deficit in France could reach €15 billion by 2035 without additional reforms. The government is considering measures such as raising the retirement age and increasing contribution rates [10][11]. - CalPERS opposes the SEC's decision to abandon ESG disclosure rules, arguing that this will prevent investors from understanding climate risks and lead to financial risks [12]. Summary by Sections Australian Pension Investments - Australian pension funds are seeking to expand their investments in the U.S. to influence the U.S. government regarding tariff policies. The AUM of the Australian pension industry is $2.6 trillion, with significant investments in private equity in the U.S. [9][10]. - The Australian government is actively engaging with U.S. officials to discuss trade relations and potential tariff eliminations [10]. French Pension System - The French Audit Court has indicated that without reforms, the pension system deficit could reach €15 billion by 2035 and €30 billion by 2045. The current surplus of €8.5 billion in 2023 is expected to turn into a deficit starting in 2024 [10][11]. - Proposed reforms include raising the retirement age and adjusting pension benefits, which may lead to social tensions [11]. ESG Disclosure Rules - CalPERS is defending the ESG disclosure rules against the SEC's decision to abandon them, emphasizing the importance of climate risk disclosure for investors [12].

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [39]. Core Insights - The report highlights that the global smart driving chip market is projected to reach $7.6 billion by 2025, representing a year-on-year growth of 51% [6][7]. - The semiconductor industry is currently in a recovery phase, driven by a rebound in consumer electronics, which is expected to initiate a new upward cycle for semiconductors [33]. - The report emphasizes the importance of high-performance, integrated chips, with those exceeding 100 TOPS expected to account for over 25% of the market by 2025 [7]. Industry Dynamics - According to Qunzhi Consulting, the penetration rate of L2 and above smart driving in new cars is expected to reach 45% by 2024, with L3 smart driving projected to account for 8.5% by 2026 [7]. - Canalys forecasts that the global personal smart audio market will see an 8% increase in shipments, reaching 533 million units by 2025 [10][11]. - The global cloud infrastructure service expenditure is anticipated to grow by 19% in 2025, following a 20% increase in 2024, driven by the rapid expansion of AI models [20][21]. Investment Recommendations - The report recommends several companies within the semiconductor sector, including Northern Huachuang, Zhongwei Company, and Tuojing Technology, as key investment opportunities [33]. - It also suggests focusing on AI and semiconductor investment opportunities, highlighting companies like Haiguang Information and Shengke Communication [33].

证券研究报告 策略周报：科技创新引领中国资产重估 证券分析师 魏伟 投资咨询资格编号：S1060513060001 陈骁 投资咨询资格编号：S1060516070001 张亚婕 投资咨询资格编号：S1060517110001 蒋炯楠 投资咨询资格编号：S1060524120002 2025年2月23日 请务必阅读正文后免责条款 1 ※ 核心观点|科技创新引领中国资产重估 2 • 上周全球权益"东升西降"，中国科技资产领涨全球。海外方面，美股市场情绪受经济数据走弱、特朗普内政外交政策扰动，三大指数下跌 1.7%-2.5%，美元指数下行0.14%至106.7。国内方面，宏观的科技产业政策支持信号+微观的创新成果催化继续支撑中资权益向上，港股恒生 科技上涨6.03%领涨全球，A股的上证指数、创业板指、科创50指数上涨0.97%、2.99%和7.07%。结构上，港股医疗保健、信息技术、通讯服 务领涨，涨幅在7%-10%左右，A股的通信、机械设备、电子行业领涨，涨幅在7%-8%左右。 • 海外方面，美国最新的服务业/消费/地产数据边际走弱，特朗普内政外交政策仍存较多不确定性。基本面上，美国最新经济数据引发市场对 经济放 ...

Investment Rating - The industry investment rating is "Outperform the Market" [1][16] Core Viewpoints - The cultural and entertainment industry is expected to experience diversified growth due to favorable national policies, leading to a continued recovery in the media sector. The report suggests that segments within the media industry may see upward opportunities based on the robust recovery logic of discretionary consumption [2] - The gaming and IP sector is anticipated to enter a new product cycle supported by government encouragement of cultural consumption. Additionally, advancements in AIGC technology may help gaming companies reduce costs and improve efficiency [2] - The film and cinema industry is gradually recovering, with an increase in the number of films being produced. The report highlights that the sustained support from policies and encouragement for cultural consumption will boost the industry's prosperity [2] - The advertising and marketing sector is recovering at a slower pace compared to the overall economic recovery, with a notable performance in elevator and station advertising. Companies with strong client structures and channel resources are expected to recover first [3] - In the digital media and publishing sectors, the report notes that leading companies have high market shares and potential for further growth. It emphasizes the importance of focusing on major players in these segments [3] Summary by Relevant Sections Gaming and IP - The gaming sector is expected to benefit from new product cycles and technological advancements, with a focus on leading companies such as 37 Interactive Entertainment, Perfect World, and Gigabit [2] Film and Cinema - The film industry is seeing a recovery in supply, with an increase in film production. Key companies to watch include Wanda Film and Light Media, which are expected to show stable recovery in performance [2] Advertising and Marketing - The advertising sector is experiencing a slow recovery, with a focus on leading companies like Focus Media and BlueFocus Communication Group, which are expected to benefit from improved profit margins [3] Digital Media and Publishing - In digital media, companies like Mango TV are highlighted for their strong market positions and potential for growth. The publishing sector is also noted for positive growth in educational and children's books [3][9]